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Abstract
Background: Autism spectrum disorders (ASDs) are a group of highly heritable neurodevelopmental disorders which 
are characteristically comprised of impairments in social interaction, communication and restricted interests/
behaviours. Several cell adhesion transmembrane leucine-rich repeat (LRR) proteins are highly expressed in the 
nervous system and are thought to be key regulators of its development. Here we present an association study 
analysing the roles of four promising candidate genes - LRRTM1 (2p), LRRTM3 (10q), LRRN1 (3p) and LRRN3 (7q) - in order 
to identify common genetic risk factors underlying ASDs.
Methods: In order to gain a better understanding of how the genetic variation within these four gene regions may 
influence susceptibility to ASDs, a family-based association study was undertaken in 661 families of European ancestry 
selected from four different ASD cohorts. In addition, a case-control study was undertaken across the four LRR genes, 
using logistic regression in probands with ASD of each population against 295 ECACC controls.
Results: Significant results were found for LRRN3 and LRRTM3 (P < 0.005), using both single locus and haplotype 
approaches. These results were further supported by a case-control analysis, which also highlighted additional SNPs in 
LRRTM3.
Conclusions: Overall, our findings implicate the neuronal leucine-rich genes LRRN3 and LRRTM3 in ASD susceptibility.
Background
Autism is a genetically complex neurodevelopmental disor-
der, characterized by impairments in reciprocal social inter-
action and communication, along with restricted and
stereotyped patterns of interests and behaviours [1]. It is an
extremely heterogeneous and highly heritable condition,
affecting predominantly males (with an average sex ratio of
4:1), and with an onset before 3 years of age [2,3]. Autism
spectrum disorders (ASDs) refers to a broad definition of
autism, including classical and atypical autism, Asperger
syndrome and pervasive developmental disorder not other-
wise specified [4]. The aetiology of ASD is not fully under-
stood and the causal variants and their modes of
transmission remain elusive.
Leucine-rich repeats (LRRs) are common protein-protein
interaction motifs and are typically 20-29 amino acids in
length [5]. LRR proteins are highly expressed in the ner-
vous system and are involved in numerous biological func-
tions, including nervous system development [5-10].
Mutations in LRR genes have been associated with differ-
ent diseases, such as hereditary lateral temporal epilepsy
[11] and Parkinson disease [12]. Furthermore, a recent
study suggested that LRR variants could possibly be
involved in ASD susceptibility [13].
From the 313 known human LRR genes (NCBI Build
36.1), this work focused on four brain-enriched LRR candi-
dates - LRRTM1, LRRTM3, LRRN1 and LRRN3. There are
several LRR subfamilies, differentiated by the consensus
sequence of the repeat and/or different combinations of
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supplementary domains [5,8,14]. One family of brain-
enriched LRR containing type I transmembrane proteins is
termed the LRRTM (leucine rich repeat transmembrane
neuronal) family [8]. This is a highly conserved four-mem-
ber family which, with the exception of LRRTM4, has the
unusual characteristic of being located in the introns of dif-
ferent α-catenin genes. Catenin family members are adhe-
sion proteins that can form a complex with cadherins,
which themselves have also been implicated in intellectual
disability, autism and ASD risk [13,15-17]. LRRTM mes-
senger (m)RNAs are mainly expressed in the nervous sys-
tem, each with a distinct and highly regulated pattern
[8,18]. It has recently been proposed that LRRTMs are syn-
aptic organizing molecules and synaptogenic inducers in
neurons, initiating excitatory presynaptic differentiation
and mediating post-synaptic specializations [19]. As sev-
eral synaptic genes have been implicated in ASD, these
genes become promising candidates to study [20].
LRRTM1  (MIM*610867), located on 2p12, lies within
intron 7 of CTNNA2 (α2-catenin) with the highest mRNA
expression in the brain and salivary gland [8]. LRRTM1 is
the first gene to be associated with both human handedness
(relative hand skill) and schizophrenia [21] and is thought
to be involved in brain development, neuronal connectivity,
intracellular trafficking in axons and synaptogenesis
[19,21]. Therefore, it is an interesting candidate for autism
where there is already some evidence for associations with
abnormal asymmetrical brain structure in language-associ-
ated areas [22,23].
Similarly, LRRTM3 (MIM*610869), on 10q22.1, is posi-
tioned within intron 7 of CTNNA3 (αT-catenin). This gene
has a more restricted expression profile compared to
LRRTM1, with expression in the brain, particularly the cer-
ebellum [8,24]. In addition, LRRTM3 is functionally and
positionally linked to late-onset Alzheimer's disease
[24,25]. Moreover, CTNNA3 has also been recently sug-
gested to be associated to ASD susceptibility [13].
The LRRN (leucine rich repeat neuronal) family of pro-
teins has four known members in humans, all being brain-
enriched type I transmembrane proteins [26]. Studies in
several species show that the members of this family have
different spatial and temporal expression patterns and that
they are involved in neural development and regeneration
[14,27-29]. Although they seem to function as adhesion
molecules or binding receptors in regulatory mechanisms,
their biological activities and specific central nervous sys-
tem (CNS) functions in humans are still unclear [30,31].
LRRN1, located on 3p26.2, is again a nested gene located
in intron 8 of the long form of SUMF1 (sulphatase modify-
ing factor 1) (NM_182760). In the developing neural cells
of the chick, Lrrn1 is localized in the endosome, suggesting
that it might be involved in the regulation of cell adhesion
and signalling pathways [32]. LRRN1 shows a high degree
of sequence conservation and comparison to its expression
in the mouse indicates that it is dynamically expressed in
the somites and the neural plate during development, and
mostly in the brain and kidney in the adult [14]. Further-
more, LRRN1 is located within a candidate region for reces-
sive non-syndromic mental retardation on chromosome 3
[33]. Additionally, a paternally inherited duplication
(3p26.1-26.2) which encompasses LRRN1 was reported in
children with autism and additional developmental abnor-
malities [34].
Finally,  LRRN3  maps to 7q31.1 and is brain-enriched
[14,31,35].  LRRN3  is a nested gene in IMMP2L  (inner
mitochondrial membrane peptidase-like), being positioned
within intron 3. The molecular structure and expression pat-
tern of Lrrn3, suggest that it plays a role in the development
and maintenance of the nervous system [14]. Other studies
have shown that Lrrn3 exhibits regulated expression in the
developing ganglia and motor neurons of the neural system,
and is upregulated during neuronal cortical injury
[14,27,28]. In addition, one of the most consistently repli-
cated loci for autism, first identified by The International
Molecular Genetic Study of Autism Consortium (IMG-
SAC) [36], is on 7q21.3-7q34 [37-43]. As LRRN3 is located
under the linkage peak of interest for IMGSAC families,
and there is evidence of an association with the IMMP2L/
DOCK4 region in the IMGSAC cohort [44], we considered
LRRN3 to be an appealing candidate for ASD susceptibility,
despite a previous study failing to find evidence of an asso-
ciation between this gene and autism in their cohorts [45].
Here, the roles of LRRTM1,  LRRTM3,  LRRN1  and
LRRN3 in ASD susceptibility were studied in four different
populations of European ancestry (IMGSAC, Italian, Ger-
man and Northern Dutch). The variation at these four loci
was assessed and the association of gene variants and hap-
lotypes with ASD was tested in a family based study. Sig-
nificant evidence of their association to ASD was found for
LRRN3 and LRRTM3. In order to complement this analysis,
a case-control study was performed, partially supporting
the evidence of association found in LRRN3 and LRRTM3.
To our knowledge, this is one of the most comprehensive
genetic analyses of association between these genes and
ASD risk.
Methods
Subjects
All the individuals who participated in this study are Cauca-
sian and of European ancestry. Four cohorts were used, our
core IMGSAC set consisting mainly of UK families, two
groups from Italy and Germany (collected as part of the
IMGSAC collaboration) and a population from the north of
the Netherlands. These cohorts are referred to as IMGSAC,
Italian, German and Northern Dutch, respectively. A total
of 2758 individuals from 661 families [439 IMGSAC (350
multiplex and 89 singleton), 85 Italian, 30 German and 107
Northern Dutch] were analysed. The male:female ratio ofSousa et al. Molecular Autism 2010, 1:7
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the affected individuals is 4.1:1. Also, a cohort of 295 UK
DNA controls [European Collection of Cell Cultures
(ECACC]) was used for the case-control study. ECACC
controls were randomly selected, non-related, UK Cauca-
sian blood donors http://www.hpacultures.org.uk/products/
dna/hrcdna/hrcdna.jsp. For the IMGSAC sample collection
the identification of families, assessment methods and
inclusion criteria used have been described previously [37].
Briefly, after identification in an initial screen for autism,
parents undertook the Autism Diagnostic Interview-
Revised (ADI-R) [46] and the Vineland Adaptive Behav-
iour Scales [47]. Probands were assessed using the Autism
Diagnostic Observation Schedule (ADOS) [48] and a clini-
cal evaluation was undertaken in order to exclude known
medical disorders aetiologically associated with autism (for
example, tuberous sclerosis and neurofibromatosis). Karyo-
types were obtained for probands when possible and molec-
ular genetic testing for fragile X syndrome carried out on
one affected case per family. A blood sample was taken
from both probands and available first degree relatives.
DNA was extracted from blood samples, buccal swabs or
cell lines using a DNA purification kit (Nucleon® BACC2
Blood and Cell Culture DNA purification kit, Tepnel Life
Sciences, Manchester, UK) and standard techniques. The
Italian and German populations had the same assessment as
that described above as they are part of the wider IMGSAC
group. For the Northern Dutch population the subjects and
their assessment are again described in detail elsewhere
[49]. In short, the families were recruited through an epide-
miological survey and an autism outpatient clinic affiliated
with the Child and Adolescent Psychiatry Center of Gronin-
gen. The diagnosis criteria were very similar to those previ-
ously described for IMGSAC (including ADI-R and ADOS
assessments) and the children's intellectual functioning was
evaluated as described by Mulder et al. [50]. DNA was
extracted from cheek cells obtained by mouth swabs from
patients, parents and siblings using the Epicentre Master-
Amp™ DNA Extraction Solution Kit (BiozymTC,
Landgraaf, the Netherlands). The study was reviewed by
the relevant ethical committees. For IMGSAC population
cohort the ethical approval was carried out by:
(a) Europe (UK - Oxfordshire Psychiatric Research Eth-
ics Committee A, under the review number O03.013 and
title name 'Identifying and understanding the actions of
autism susceptibility genes'; Cambridge Local Research
Ethics Committee; Institute of Psychiatry Ethical Research
Committee; Joint Ethics Committee (Newcastle & North
Tyneside Health Authority/Universities of Newcastle upon
Tyne/Northumbria); Salford and Trafford Research Ethics
Committee/Denmark  - Den Videnskabsetiske Komite,
Kobenhavns Amt/Finland - Ethical Committee for the Hos-
pital of Children and Adolescents and Psychiatry (Univer-
sity Central Hospital)/France  - Comité Consultatif de
Protection des Personnes dans la Recherche Biomédicale
Groupe Hospitalier Pitié-Salpêtrière-Paris/Germany  -
Ethik-Kommission des Fachbereichs Medizin der Johann
Wolfgang Goethe (Universität Frankfurt am Main); Heidel-
berg Ethikkommission der Medizinischen Fakultät/Greece -
Agia Sophia Hospital Ethics Committee/Italy - Comitato
Etico IRCCS Fondazione Stella Maris/Netherlands  -
Medisch Ethische Toetsingscommissie/Sweden  - Ethical
Review Board of Sahlgren's Academy, Goteborg University
Faculty of Medicine
(b) USA - Yale University School of Medicine Human
Investigation Committee; University of Illinois at Chicago's
Office for the Protection of Research Subjects; University
of Michigan Medical School IRBMED
(c) Canada - The Hospital for Sick Children, Research
Ethics Board; Hamilton Health Sciences/McMaster Univer-
sity Research Ethics Board.
For the Northern Dutch population cohort, ethical review
was done by the Medical Ethical Committee of the Univer-
sity Medical Center Groningen under review number
M08.057360.
Written informed consent was provided by all parents/
guardians and, when possible, by the affected individuals.
The IMGSAC cases are Caucasian, but from different sites
in Europe and the USA. Therefore, population substructure
is a distinct possibility. The samples used for the current
study have substantial overlap with the IMGSAC samples
described in Maestrini et al. [44], where no evidence of
strong population stratification was detected. However, it is
possible that subtle or low levels of population stratification
may be present, potentially leading to false positives in the
case-control analysis.
Genotyping
Single nucleotide polymorphism (SNP) selection
Genotyping data from Centre d'Etude du Polymorphisme
Humain individuals was downloaded from the HapMap
phase II (release 24) for each gene and approximately 5 kb
of upstream and downstream sequence. This resulted in
information for the four following regions being obtained:
2p12 (80381256-80386255); 10q22.1 (68353045-
68532626); 3p26.2 (3814162-3866687); and 7q31.1
(110516705-110554408). Sixty-seven haplotype tagging
SNPs were chosen across these loci using Tagger from
Haploview v4.0 [51] [r2 > 0.8 and minor allele frequency
(MAF) > 0.05, aggressive tagging], capturing the maximum
amount of genetic variation in the four regions. In addition,
one 3'untranslated region and two synonymous SNPs in
LRRTM1 were genotyped, as these were the only markers
left to genotype in order to complete the whole coverage of
this region.
Sequenom assay
The genotyping assay was designed using the MassARRAY
software (Sequenom) and genotypes obtained using the
MassARRAYTyper™ system (version 3.1.4.0). Quantifica-Sousa et al. Molecular Autism 2010, 1:7
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tion of DNA samples was performed using the
Picogreen®dsDNA Quantitation Kit (Invitrogen, Oregon,
USA) and 40 ng of genomic DNA per sample was used in
the genotyping assay. Genotyping was performed using the
Sequenom MALDI-TOF iPLEX platform (Sequenom, San
Diego, USA). The sample and marker genotyping success
rates were ~98% and 94%, respectively. Based on two con-
trol samples included on each plate as genotyping controls,
we found high inter-plate reproducibility (99.8%). Geno-
type Analyzer (Sequenom) was used to visually check the
quality of each genotype call, assigning alleles where possi-
ble. An in-house database [52] was used to store all geno-
typic data and to produce files for statistical analysis.
Statistical analysis
Error checking
Genotypes were checked for Mendelian consistency using
PedCheck [53] and any inconsistent genotypes were
removed. Genotypes flanking double recombinants were
detected using MERLIN [54] and, in ambiguous cases
where probable excess recombination occurred, genotypes
were reconfirmed and corrected as necessary. All the SNPs
were tested for Hardy-Weinberg equilibrium using a χ2 test,
in parents and probands separately.
Association analysis
The pairwise linkage disequilibrium (LD) maps for LRRN1,
LRRN3  and  LRRTM3  were constructed from genotypes
using the Haploview software (Figure 1). SNP and haplo-
type association in families was assessed using the trans-
mission disequilibrium test (TDT) [55], with a version
robust to non-independent siblings implemented [56],
allowing for the use of multiple siblings within a nuclear
family. Allele frequencies were reported for all the parents
and children. From applying the TDT, the allele transmis-
sion frequencies from parents to offspring were also esti-
mated. Parental transmissions were also analysed for each
SNP to consider parent-of-origin effects. In order to com-
bine the evidence across all cohorts at each polymorphism,
we estimated odds ratios (ORs) and their standard errors
from transmission frequencies [57] and then performed a
meta-analysis pooling using an inverse variance approach
[58]. Also, at each polymorphism we performed a chi-
square test of heterogeneity of the ORs [58]. Meta-analysis
forest plots were constructed for each marker using the
meta library in the R statistical software http://www.r-proj-
ect.org. A haplotype-based TDT analysis was also carried
out using TRANSMIT [56]. For each haplotype, risk esti-
mates and their 95% credibility internals were estimated
using a Bayesian method [55,56]. Logistic regression was
used in the analysis of both the alleles and genotypes in the
case-control study. When we were analysing cases from the
same family, we performed a weighted logistic analysis
where each family contributed the same weight. In the
logistic regression framework, testing on the genotypes (for
example, dd, DD and Dd) without regard to any 'order',
allelic count or allelic pairing was performed. In particular,
we investigated several related genotypic mechanisms: (i)
an additive model which assesses the influence of increas-
ing the number of minor alleles (0,1,2) on log-risk; (ii)
dominant model (of the 'd' allele: dd/Dd versus DD); (iii)
recessive model (of 'd': dd versus Dd/DD); (iv) heterozy-
gous advantage (Dd versus DD/dd); (v) general model (dd
versus DD, Dd versus DD). We report the minimum P-
value from these correlated tests. Meta-analytic approaches
were also applied to pool the resulting allele- and genotype-
based ORs across populations.
Multiple testing correction
Performing multiple statistical tests leads to inflation in the
occurrence of false positives and it is therefore necessary to
adjust the statistical significance (P-value) threshold (usu-
ally 5%) in order to account for the number of independent
tests. A Bonferroni correction using the total number of
SNPs would be too conservative because of the high LD
between SNPs in the analysed regions [56]. By considering
the LD pattern, which identified 10 independent haplotype
blocks, it is reasonable to interpret using a P < 0.005 (=
0.05/10) to be statistically significant. Using a separate per-
mutation approach we found a similar (5%) significance
threshold (P < 0.0048) based on inference of the maximum
chi-square statistic observed over all genotyped SNPs. In
particular, both the transmitted/untransmitted and case-con-
trol status of the chromosomes were randomly permuted
10,000 times. From each of the 10,000 random experi-
ments, in both trio and case-control studies, we determined
the maximum chi-square statistics over all SNPs geno-
typed. We ordered these statistics and then calculated the 95
percentile. This was the estimate of the 0.05 significance
level for the experiment performed, assuming inference is
taken with respect to maximum chi-square statistic
observed over all genotyped SNPs.
Results
Family-based studies
Sixty-six markers (from the 70 in total) were successfully
genotyped across these loci. One marker in LRRTM1
(rs34285492) and three in LRRTM3  (rs1925574,
rs1925575, rs6480244) failed and were removed from the
analysis. For the remaining markers, genotype and allele
frequencies were calculated from cases and parents for each
population across the genes under study. Furthermore, two
markers - rs2290170 (LRRTM1) and rs12098475
(LRRTM3) - were monomorphic in the populations studied.
The SNPs analysed were in Hardy-Weinberg equilibrium in
both probands and founders (P  > 0.001). TDT statistics
were performed for all markers in each population to test
for association between the four leucine-rich repeat (LRR)
genes and ASD, and it was considered reasonable to inter-
pret a P < 0.005 to be statistically significant (see MaterialsSousa et al. Molecular Autism 2010, 1:7
http://www.molecularautism.com/content/1/1/7
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and Methods). For the IMGSAC families, the analysis was
carried out as two groups, since both multiplex and single-
ton families were present. This follows the suggestions that
these two groups have different underlying aetiologies and
so could contribute in distinct manners to disease suscepti-
bility and, consequently, should be addressed separately
[59,60]. A meta-analysis using the entire data was also car-
ried out to weigh and summarize the results obtained with
the multiple single TDT tests. The results are shown for
each population and for the pooled meta-analysis in Figure
2. Meta-analysis forest plots were constructed for each
marker (data not shown) and the six most significant mark-
ers from the overall meta-analysis are illustrated in Figure
3. No significant findings were obtained with the LRRTM1
gene analysis. One marker (rs1488454) in LRRN1 showed
statistically significant transmission disequilibrium, having
a preferential transmission of the C allele to the affected
offspring (P = 0.002 - Additional File 1 and Figure 2). This
significance was present in the singleton cohort within the
IMGSAC subgroup, as confirmed in the corresponding for-
est plot where this population shows an OR deviation from
1 (Figure 3a). For LRRN3, the marker rs10261004 was sig-
nificant in the Northern Dutch cohort (P = 0.001 - Addi-
tional File 2 and Figure 2). This is shown in the respective
forest plot for this subgroup (Figure 3c), with the condition
less likely in individuals who carry the G allele (as the OR
is below 1). Moreover, the two neighbouring markers were
also of nominal significance in the same population. How-
Figure 1 The graphical output from Haploview. The markers tested and the haplotype blocks constructed for (a) LRRN1, (b) LRRN3 and (c) LRRTM3 
are included. D' values are indicated (bright red corresponds to D' = 1, with the colour tending towards white as D' tends towards 0).Sousa et al. Molecular Autism 2010, 1:7
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ever, this significance was not present after adjusting for
multiple testing corrections. In LRRTM3, two SNPs -
rs1998753 (P = 0.001) and rs12266823 (P = 0.001 - Addi-
tional File 3 and Figure 2) - showed statistically significant
transmission disequilibrium. For these markers the signifi-
cance was being driven especially by the multiplex cohort.
However, the pooled meta-analysis was also significant for
rs12266823 (Figure 2), showing that other groups were also
contributing to the association in the same direction. Fur-
thermore, the respective forest plots (Figure 3d-e) show that
the G allele for rs1998753 confers an increased risk for
ASD, while the A allele for rs12266823 confers a decreased
risk. Additionally, rs10997476 had nominal significance,
especially in the multiplex samples (Figure 3f), but the sig-
nificance did not remain after we adjusted for multiple test-
ing. The empirical P-values for all TDTs performed are
reported in Additional Files 1 to 6, and the significant ones
are highlighted in bold. Parental transmissions were exam-
ined for each marker, but no evidence of parent-of-origin
effects was found (P > 0.12).
Examination of the LD patterns across LRRN1, LRRN3
and LRRTM3 loci, using our genotyping data, showed that
each gene defined four, two and four LD blocks, respec-
tively (r2 > 0.8 and MAF > 0.05; Figure 1). In contrast, the
SNPs tested in LRRTM1 defined no LD blocks. 'The human
genome can be parsed objectively into haplotype blocks:
sizable regions over which there is little evidence for histor-
ical recombination and within which only a few common
haplotypes are observed' [61], which I will call LD blocks.
'If haplotype blocks represent regions inherited without
substantial recombination in the ancestors of the current
population, then a biological basis for defining haplotype
blocks is to examine patterns of recombination across each
region. The history of recombination between a pair of
SNPs can be estimated with the use of the normalized mea-
sure of allelic association, D' '[61]. 'We define pairs to be in
"strong LD" if the one-sided upper 95% confidence bound
on D' is >0.98 (that is, consistent with no historical recom-
bination) and the lower bound is above 0.7' [61]. Haplotype
analysis was performed in order to further assess the trans-
mission disequilibrium within the LD blocks, as haplotypes
can sometimes offer more power to detect association com-
pared to single SNPs. Transmission of haplotypes, includ-
ing all markers within each block, was tested using
Transmit [56], along with the multi-marker haplotype com-
Figure 2 Transmission disequilibrium test results for each population and overall meta-analysis results, across the four genes under study. 
The significance is represented on the y-axis, plotted as -log10(P-value), and on the x-axis is shown each marker studied. The dashed line represents 
the statistical significance threshold of 0.005.
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binations from the Tagger output (since the haplotype tag-
ging SNPs were chosen using aggressive tagging). In the
overall population, only one significant haplotype specific
result was obtained, for a Tagger multi-marker haplotype
within LRRTM3 (Table 1). This haplotype contains marker
rs12266823 that showed high significance in the single
locus association test. Additionally, the two markers in
intron 2 (rs6480245 and rs12266823) that comprise this
haplotype are in high LD with each other (D' = 87 - Figure
1c). However, for haplotype GA (P = 0.0005 - Table 1) the
significance of the haplotype was increased compared to
the single marker, suggesting that this specific haplotype
could potentially increase susceptibility to ASD. Two three-
marker haplotypes (rs716546-rs716547-rs9971243) were
also over-transmitted to the affected offspring, revealing a
possible transmission distortion in LD block 2. However,
the significance was above the 0.005 significance threshold
established previously and none of the markers that make
the haplotypes are in high LD with the significant markers
from the single locus TDT test. The same analysis was car-
ried out for separately each gene across the five subgroups
of samples and only the haplotype specific P-values
approaching or below the nominal significance threshold of
P < 0.05 are shown (Table 2). No significant results were
obtained with the German and Italian populations or with
LRRTM1. Taking each population into account, although
some results reach nominal significance for LRRN1  and
LRRTM3, they were all above the 0.005 significance thresh-
old previously established. However, for the Northern
Dutch population, LRRN3 showed a transmission distortion
in LD block 2 with the two-marker (rs10261004 and
rs214884) haplotypes GC (P = 0.005 - Table 2) and TT (P =
0.004 - Table 2). However, these haplotypes both contain
rs10261004 which, alone, was significant and is most prob-
ably driving the association in this case, as the significance
was not increased compared to the single locus result.
Figure 3 Forest Plots of the six most significant markers from the transmission disequilibrium test (TDT) analyses. (a) rs1488454 (LRRN1); (b) 
rs12054065 (LRRN1); (c) rs10261004 (LRRN3); (d) rs1998753 (LRRTM3); (e) rs12266823 (LRRTM3); and (f) rs10997476 (LRRTM3). For each marker, the results 
for each population and for the overall meta-analysis TDT are represented. The population's labels correspond respectively to: German, ND (Northern 
Dutch), Italian, singleton families (IMGSAC) and multiplex families (IMGSAC). For each marker, the odds ratio (OR) is represented on the x-axis, and on 
the y-axis is shown the point estimate and its 95% confidence interval (CI). The overall meta-analysis estimate and its CI are at the bottom, represented 
as a diamond (indicating the pooled point estimate). The size of the black square represents the amount of data analysed for each population. The 
vertical bold line shows the no effect point (OR = 1) and the dotted line shows the overall effect point.
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Case-control study
A case-control study was conducted in parallel, testing
probands with ASD against unselected controls, using
allele and genotype data from the same 66 SNPs genotyped
across the four LRR genes. Minor allele frequencies from
controls and cases for each population across the genes
under study were calculated and the SNPs were in Hardy-
Weinberg equilibrium in both (P  > 0.001). Case-control
analysis was carried out using logistic regression in
probands of each population against the 295 ECACC con-
trols. Results for the allelic tests of association applied to
each sample cohort and for the overall meta-analysis are
shown in Figure 4 and, again, P < 0.005 were considered
significant. In order to complement and further describe the
latter, the most significant results for the genotypic tests of
association performed are shown in Table 3. The allelic
case control analysis highlighted nine SNPs in total. One
marker in LRRN3  (rs10261004) and one in LRRTM3
(rs1998753) were again significant, confirming the results
of the single locus TDT study. For rs10261004 the associa-
tion was detected in the Northern Dutch cohort (consistent
with earlier results) and tests of association indicated a
decreased risk for the G allele compared with the T (G ver-
sus T: P = 0.001; additive G: P < 0.003). The rs1998753
association is being driven by the Northern Dutch cohort (A
versus G: P < 0.00001; AG versus GG/AA: P < 0.00001),
with the other cohorts all having non-significant ORs less
than 1 (A versus G: P = 0.21; AG versus GG: P = 0.48).
Across all populations there were no 'AA' genotypes for
rs1998753 and the minor allele frequencies were low (A
allele: <5%), except in the Northern Dutch cohort (A allele:
MAF 0.234), consistent with family-based frequencies.
Additionally, there were seven new significant results (P <
0.005) located in LRRTM3 (rs17279006, rs1925613,
rs10997482, rs1925594, rs2619652, rs10740268 and
rs12785206; Figure 4). The first three polymorphisms
(rs17279006, rs1925613, rs10997482) were found to be
significant in the overall meta-analysis. The overall results
of association tests were: rs17279006 (G versus A: P  <
0.002; additive G: P < 0.003), rs1925613 (C versus A: P <
0.00006; additive C: P < 0.00008) and rs10997482 (G ver-
sus A: P < 0.000006; additive G: P < 0.00001). The mark-
ers rs1925613 and rs10997482 were most significant in the
singleton cohort (rs1925613, C versus A, P < 0.0006; addi-
tive C, P  < 0.0009; and rs10997482, G versus A, P  =
0.0004; additive A: P < 0.0007). For rs1925594, there was a
trend towards increased risk for the C allele compared with
the T in the Italian population and in the meta-analysis.
However, the number of allele counts is too low to reach a
confident conclusion about this result. The marker
rs2619652 was significant in the overall meta-analysis and,
in particular, in the singleton cohort, presenting an
increased risk for the C allele compared with the T (P <
0.0007; additive T: P < 0.002). The marker rs10740268 was
only significant in the overall meta-analysis, showing an
increased risk for the C allele compared with T (P  <
0.00002; additive C: P  < 0.00003). Lastly, the marker
rs12785206 was, again, more significant in the singleton
cohort, having a decreased risk of the C allele compared
with the T (P < 0.0007; CC/CT versus TT: P = 0.0004).
Overall, the case-control provides increasing evidence of
significant association between LRRTM3 and ASD suscep-
tibility, not only by confirming the association with
rs1998753 but also through the new significant results
within the gene.
Discussion
Recently, there has been increasing attention towards the
LRR group of transmembrane proteins and their relation-
ship with neurological complex disorders. The LRRs analy-
sed here are thought to be synaptic organizing molecules
and have been implicated in brain development, which is
Table 1: Haplotype transmission disequilibrium results in the overall population across leucine-rich repeat 
transmembrane neuronal (LRRTM3). 
LD block/Tagb Haplotypea TR NT OR CI P-value
Block 2 (rs716546-rs716547-rs9971243) CCT 75 52 1.44 (1.01, 2.05) 0.0505
Block 2 (rs716546-rs716547-rs9971243) CTC 2 10 0.20 (0.04, 0.91) 0.0386
rs6480245, rs12266823b GA 44 84 0.52 (0.36, 0.75) 0.0005
rs6480245, rs12266823b GC 242 186 1.30 (1.07, 1.58) 0.0078
The analysis was performed within each linkage disequilibrium (LD) block for each gene and for the haplotype combinations from Haploview 
(selected by Tagger). Only haplotypes approaching or below the nominal significance threshold of P < 0.05 are shown.
aHaplotypes only reported if there are more than 10 informative transmissions in total.
bHaplotype combinations selected by Tagger.
CI, confidence interval; NT, non-transmitted; OR, odds ratio; SNP, single nucleotide polymorphism; TR, transmitted.S
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Table 2: Haplotype transmission disequilibrium results per population across the four genes studied. 
Gene LD block/Tagb Hapa IMGSAC (Multiplex families) IMGSAC (Singleton families) Northern Dutch
TR NT OR/CI P-
value
TR NT OR/CI P-
value
TR NT OR/CI P-
value
LRRN3 Block 2 
(rs10261004-
rs214884)
GC 92 6 0 . 3 5  
(0.16, 0.74)
0.005
LRRN3 Block 2 
(rs10261004-
rs214884)
TT 44 20 2.20 
(1.30, 3.73)
0.004
LRRN1 Block 3 
(rs10510278-
rs696489)
AC 98 70 1.40 
(1.03, 1.90)
0.037
LRRN1 Block 3 
(rs10510278-
rs696489)
TT 61 85 0.72 
(0.52, 1.00)
0.057
LRRN1 rs10780025, 
rs13100776b
AT 18 37 0.49 
(0.28, 0.85)
0.014
LRRTM3 rs1925613, 
rs10762138b
CT 8 20 0.40 
(0.18, 0.91)
0.036
LRRTM3 rs1925613, 
rs1925624b
AT 139 102 1.36 
(1.06, 1.76)
0.020
LRRTM3 rs2619652, 
rs12785206b
CC 18 7 2.57 
(1.07, 6.16)
0.043
LRRTM3 rs2619652, 
rs12785206b
TT 9 22 0.41 
(0.19, 0.89)
0.029
LRRTM3 rs1925613, 
rs12785206b
CT 8 21 0.38
 (0.17, 0.86)
0.024
The analysis was performed within each linkage disequilibrium (LD) block for each gene and for the haplotype combinations from Haploview (selected by Tagger). Only haplotypesa approaching or below the nominal significance threshold of P < 0.05 are shown.
aHaplotypes only reported if there are more than 10 informative transmissions in total.
bHaplotype combinations selected by Tagger.
CI, confidence interval; Hap, Haplotype; NT, non-transmitted; OR, odds ratio; SNP, single nucleotide polymorphism; TR, transmitted.Sousa et al. Molecular Autism 2010, 1:7
http://www.molecularautism.com/content/1/1/7
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often impaired in autistic individuals [8,14,18,19,21,32]. In
the current study, we hypothesized that common variants in
the leucine motifs gene class could possibly be involved in
ASD pathogenesis. Specifically, LRRTM1,  LRRTM3,
LRRN1 and LRRN3 were examined as candidate genes in
four different populations of European ancestry by carrying
out parallel family-based and case-control studies.
LRRN1  showed only one significant result with the
marker rs1488454, showing that its C allele is increasing
the susceptibility to ASDs in the singleton cohort. However,
this result was not confirmed by the case-control analysis
which points to a weaker evidence for a role in susceptibil-
ity.
The family based study showed that rs10261004 within
LRRN3 is strongly associated with ASD risk in the North-
ern Dutch cohort and that its G allele is protective for sus-
ceptibility to the disorder. The haplotype analysis also
showed evidence of significance with two haplotypes
within LD block 2. Moreover, the case-control analysis
confirmed the evidence of an association with this marker,
showing a decreased risk for the G allele and for the GG/
GT genotypes (compared to the T allele and TT genotype,
respectively). This is the most consistent result that we have
found, as the marker is significant in all the tests performed
in the Northern Dutch cohort and, therefore, it could be a
population specific susceptibility. The non-association
reported for this gene in the Collaborative Linkage Study of
Autism dataset by Hutcheson et al. [45] could be explained
by several factors: differences in sample ascertainment,
family numbers and the hypothesis that one of the results is
a false positive. In effect, they tested 30 nuclear families,
which could have limited their ability to detect the associa-
tion signal that we are observing in our cohort. In addition,
none of the four markers tested in their study were in high
LD with rs10261004.
LRRTM3  was the gene that showed most evidence of
association in the populations that we studied. In particular,
rs1998753 was the most consistent significant marker
within this gene, showing that its G allele increases the risk
for ASD, especially in the multiplex cohort (but was also
significant in the pooled meta-analysis). Although this
effect was evident in all case-control cohorts except the
Northern Dutch, it did not reach a significant level of statis-
tical evidence. In fact, in the Northern Dutch case-control
Figure 4 Case-control allele-based tests of association performed for each population and for the overall meta-analysis. The significance is 
represented on the y-axis, plotted as -log10(P-value) and on the x-axis is shown each marker studied. The dashed line represents the statistical signifi-
cance threshold of 0.005. 'Overall' represents the pooled meta-analysis performed.
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cohort, which is a more isolated population than the others,
there is strong evidence that the A allele increases the risk
for ASD and that there is a non-significant over-transmis-
sion of the A allele to cases in the TDT. Consequently, for
the case-control, although the Northern Dutch result could
be a false positive, it biases the overall results. The statisti-
cal power of the case-control analysis is hindered by the
small sample size of our control cohort, by sampling cases
from a population possibly different to the others and by
false positives which were possibly due to the population
structure. In contrast, the family-based study is robust to
population stratification. So, although the case-control
result can be taken as a verification of the positive evidence
of association with this marker, this result warrants further
confirmation that could be achieved by another replication
study or by genotyping a larger control group for this
marker, preferably including a set of controls from the
Northern Dutch population. In addition to rs1998753,
rs12266823 was also significant, with the A allele being
protective against ASD risk in the multiplex cohort and in
the pooled meta-analysis of the TDT. However, this result
was not confirmed by the case-control analysis. Neverthe-
less, new associations within LRRTM3 were found in the
case-control study with the markers rs17279006,
rs1925613, rs10997482, rs2619652, rs10740268 and
rs12785206. All of these were significant in the overall
analysis. For rs17279006 the G allele and GG(/GT) geno-
types were protective against the disorder, whereas for the
rs1925613 C allele, and CC(/CA) and rs10997482 G allele
and GG(/GA) genotypes, the risk of ASD was increased
(the last two markers being most significant in the singleton
cohort in the genotypic test). For rs10740268 the C allele
Table 3: Case-control genotype-based test results. 
SNP Population Model OR CI P-value
rs10261004 Northern Dutch Additive G 0.44 (0.26, 0.75) 3.00E-03
rs10261004 Northern Dutch TT versus GG/GT 2.42 (1.33, 4.41) 4.00E-03
rs1998753 Northern Dutch Additive G 0.10 (0.05, 0.20) 5.68E-12
rs1998753 Northern Dutch AG versus GG/AA 9.64 (5.06, 18.38) 5.68E-12
rs17279006 Overall Additive G 0.62 (0.45, 0.84) 2.22E-03
rs17279006 Overall AA versus GG/AG 1.65 (1.19, 2.29) 2.59E-03
rs17279006 Multiplex (IMGSAC) AA versus GG/AG 2.14 (1.28, 3.59) 3.96E-03
rs17279006 Multiplex (IMGSAC) Additive G 0.49 (0.30, 0.79) 4.00E-03
rs1925613 Overall CC versus AA/AC 1.81 (1.37, 2.39) 2.97E-05
rs1925613 Overall Additive C 1.35 (1.16, 1.57) 7.82E-05
rs1925613 Singleton (IMGSAC) CC versus AA/AC 3.01 (1.66, 5.47) 2.81E-04
rs1925613 Singleton (IMGSAC) Additive C 1.80 (1.27, 2.54) 8.97E-04
rs10997482 Overall Additive G 1.38 (1.20, 1.60) 9.81E-06
rs10997482 Overall GG versus AA/AG 1.60 (1.27, 2.00) 4.63E-05
rs10997482 Singleton (IMGSAC) Additive A 0.54 (0.38, 0.77) 6.85E-04
rs10997482 Singleton (IMGSAC) GG versus AA/AG 2.41 (1.45, 4.03) 7.45E-04
rs2619652 Overall Additive T 0.76 (0.67, 0.88) 1.57E-04
rs2619652 Overall TT versus CC/CT 0.63 (0.49, 0.81) 2.71E-04
rs2619652 Singleton (IMGSAC) Additive T 0.58 (0.41, 0.82) 1.95E-03
rs2619652 Singleton (IMGSAC) TT versus CC/CT 0.34 (0.17, 0.69) 2.56E-03
rs10740268 Overall TT versus CC/CT 0.51 (0.38, 0.70) 2.16E-05
rs10740268 Overall Additive C 1.84 (1.38, 2.45) 3.48E-05
rs12785206 Overall TT versus CC/CT 1.49 (1.20, 1.86) 3.96E-04
rs12785206 Singleton (IMGSAC) CC/CT versus TT 0.37 (0.22, 0.65) 4.20E-04
rs12785206 Singleton (IMGSAC) Additive C 0.48 (0.31, 0.74) 1.00E-03
Only the most significant results are shown (P < 0.005).  SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.Sousa et al. Molecular Autism 2010, 1:7
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and CC(/CT) genotypes there was an increasing risk to
ASDs in the overall meta-analysis. Moreover, rs2619652
and rs12785206 were both significant in the singleton
cohort; the first presenting an increased risk for the C allele
and CC (/CT) genotypes and the second having a decreased
risk for the C allele and CC/CT genotypes. Therefore, over-
all there is growing evidence that LRRTM3 may play a role
in ASD susceptibility.
Interestingly, significant results from the TDT analysis
were only replicated in the case-control study for two mark-
ers. However, seven new significant markers appeared in
the latter that were not previously identified by the TDT.
Several explanations can be proposed for this occurrence
but the most evident is the use of different analytical
approaches. Both TDT and case-control studies use differ-
ent methods to access association, and while the TDT is
more robust to population stratification, the case-control
has in general more power to detect association in studies
such as ours. We cannot exclude the possibility that subtle
population structure (detected using many hundreds or
thousands of markers) may lead to false positive results in
the case-control analyses above. We suggest further that
there should be an assessment of the case-control specific
association markers in a larger number of controls and, if
possible, a correction for population structure or other con-
founding effects using many more markers. The two analy-
ses presented complement each other and reflect the
complex heterogeneity of the disorder spectrum, pointing
once more to the difficulty of studying ASDs. Additionally,
different markers within LRRTM3 were differently associ-
ated to multiplex and singleton families, supporting the the-
ory that we are looking at genetically different groups
within the same population that have different patterns of
ASD traits [59,60].
As both associated genes, LRRTM3  and  LRRN3, are
nested, they are possibly transcriptionally co-regulated with
the genes that contain them (CTNNA3  and  IMMP2L,
respectively) [8]. Unknown regulatory mechanisms could
be present in these regions altering gene expression or even
splicing patterns which, in turn, could contribute to ASD
susceptibility. Moreover, Wang et al. found an association
with autism with one intronic marker (rs9651325) in
CTNNA3, which is located 3' to LRRTM3, a region that was
not covered by our study [13]. Both these LRR genes war-
rant further investigation as they are highly expressed in the
brain, particularly the cerebellum, [8,14] (a characteristi-
cally impaired region in autistic individuals [62,63]),
involved in central nervous system development and regen-
eration [8,14,27,28,31], and there is accumulating evidence
implicating these genic regions in ASD susceptibility
[13,44].
Conclusions
Taken together, there is converging evidence that common
genetic variants in LRRTM3 and LRRN3 confer susceptibil-
ity to ASD and further study of these genes and their func-
tion will provide valuable insights into their role in ASD
pathogenesis. In summary, this is one of the first studies to
show results of an association between more than one leu-
cine-rich repeat gene and ASD susceptibility in populations
of European ancestry.
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